The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.
1.1 Adjuvant Treatment
Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
1.2 First-Line Treatment
Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.
1.3 Second-Line Treatment
Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets.
2.1 Recommended Dose
The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, anastrozole was administered for five years
[see Clinical Studies (
No dosage adjustment is necessary for patients with renal impairment or for elderly patients
[see Use in Specific Populations (
2.2 Patients With Hepatic Impairment
No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment
[see Use in Specific Populations (
3 Dosage Forms And Strengths
The tablets are white to off-white, round biconvex, film coated tablets, with “AHI” debossing on one side and plain on other side.
4.1 Pregnancy And Premenopausal Women
Anastrozole may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. Anastrozole is contraindicated in women who are or may become pregnant. There are no adequate and well-controlled studies in pregnant women using anastrozole. If anastrozole is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus or potential risk for loss of the pregnancy
[see Use in Specific Populations (
Anastrozole is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. Observed reactions include anaphylaxis, angioedema, and urticaria
[see Adverse Reactions (
5.1 Ischemic Cardiovascular Events
In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with anastrozole in the ATAC trial (17% of patients on anastrozole and 10% of patients on tamoxifen). Consider risk and benefits of anastrozole therapy in patients with pre-existing ischemic heart disease
[see Adverse Reactions (
5.2 Bone Effects
Results from the ATAC trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline. Patients receiving tamoxifen had a mean increase in both lumbar spine and total hip BMD compared to baseline. Consider bone mineral density monitoring in patients treated with anastrozole
[see Adverse Reactions (
During the ATAC trial, more patients receiving anastrozole were reported to have elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively)
[see Adverse Reactions (
6 Adverse Reactions
Serious adverse reactions with anastrozole occurring in less than 1 in 10,000 patients, are: 1) skin reactions such as lesions, ulcers, or blisters; 2) allergic reactions with swelling of the face, lips, tongue, and/or throat. This may cause difficulty in swallowing and/or breathing; and 3) changes in blood tests of the liver function, including inflammation of the liver with symptoms that may include a general feeling of not being well, with or without jaundice, liver pain or liver swelling
[see Adverse Reactions (
Common adverse reactions (occurring with an incidence of ≥10%) in women taking anastrozole included: hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, bone pain, peripheral edema, increased cough, dyspnea, pharyngitis and lymphedema.In the ATAC trial, the most common reported adverse reaction (>0.1%) leading to discontinuation of therapy for both treatment groups was hot flashes, although there were fewer patients who discontinued therapy as a result of hot flashes in the anastrozole group.Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
- Adverse reaction data for adjuvant therapy are based on the ATAC trial
- [see Clinical Studies (14.1)]. The median duration of adjuvant treatment for safety evaluation was 59.8 months and 59.6 months for patients receiving anastrozole 1 mg and tamoxifen 20 mg, respectively.
- Adverse reactions occurring with an incidence of at least 5% in either treatment group during treatment or within 14 days of the end of treatment are presented in Table 1.Table 1 -Adverse reactions occurring with an incidence of at least 5% in either treatment group during treatment, or within 14 days of the end of treatment in the ATAC trial
- The combination arm was discontinued due to lack of efficacy benefit at 33 months of follow-up.Body system and adverse reactions byCOSTART
- COSTART Coding Symbols for Thesaurus of Adverse Reaction Terms.preferred term
- A patient may have had more than 1 adverse reaction, including more than 1 adverse reaction in the same body system.Anastrozole 1 mg(N
- N=Number of patients receiving the treatment. = 3092)
- Tamoxifen 20 mg(N
- = 3094)
- Body as a wholeAsthenia575 (19)544 (18)Pain533 (17)485 (16)Back pain321 (10)309 (10)Headache314 (10)249 (8)Abdominal pain271 (9)276 (9)Infection285 (9)276 (9)Accidental injury311 (10)303 (10)Flu syndrome175 (6)195 (6)Chest pain200 (7)150 (5) Neoplasm162 (5)144 (5) Cyst138 (5)162 (5)CardiovascularVasodilatation1104 (36)1264 (41)Hypertension402 (13)349 (11)DigestiveNausea343 (11)335 (11)Constipation249 (8)252 (8)Diarrhea265 (9)216 (7)Dyspepsia206 (7)169 (6)Gastrointestinal disorder210 (7)158 (5)Hemic and lymphaticLymphedema304 (10)341 (11)Anemia113 (4)159 (5)Metabolic and nutritionalPeripheral edema311 (10)343 (11)Weight gain285 (9)274 (9)Hypercholesterolemia278 (9)108 (3.5)MusculoskeletalArthritis512 (17)445 (14)Arthralgia467 (15)344 (11)Osteoporosis325 (11)226 (7)Fracture315 (10)209 (7)Bone pain201 (7)185 (6)Arthrosis207 (7)156 (5)Joint Disorder184 (6)160 (5)Myalgia179 (6)160 (5)Nervous systemDepression413 (13)382 (12)Insomnia309 (10)281 (9)Dizziness236 (8)234 (8)Anxiety195 (6)180 (6)Paresthesia215 (7)145 (5)RespiratoryPharyngitis443 (14)422 (14)Cough increased261 (8)287 (9)Dyspnea234 (8)237 (8)Sinusitis184 (6)159 (5)Bronchitis167 (5)153 (5)Skin and appendagesRash333 (11)387 (13)Sweating145 (5)177 (6)Special SensesCataract Specified182 (6)213 (7)UrogenitalLeukorrhea86 (3)286 (9)Urinary tract infection244 (8)313 (10)Breast pain251 (8)169 (6)Breast Neoplasm164 (5)139 (5)Vulvovaginitis194 (6)150 (5)Vaginal Hemorrhage
- Vaginal Hemorrhage without further diagnosis.122 (4)180 (6)Vaginitis125 (4)158 (5)Certain adverse reactions and combinations of adverse reactions were prospectively specified for analysis, based on the known pharmacologic properties and side effect profiles of the two drugs (see Table
- Table 2 — Number of Patients with Pre-specified Adverse Reactions in ATAC Trial
- Patients with multiple events in the same category are counted only once in that category.AnastrozoleN=3092(%)TamoxifenN=3094(%)Odds-ratio95% CIHot Flashes1104 (36)1264 (41)0.800.73 to 0.89Musculoskeletal Events
- Refers to joint symptoms, including joint disorder, arthritis, arthrosis and arthralgia.1100 (36)911 (29)1.321.19 to 1.47Fatigue/Asthenia 575 (19)544 (18)1.070.94 to 1.22Mood Disturbances 597 (19)554 (18)1.100.97 to 1.25Nausea and Vomiting393 (13)384 (12)1.030.88 to 1.19All Fractures315 (10)209 (7)1.571.30 to 1.88Fractures of Spine, Hip, or Wrist133 (4)91 (3)1.481.13 to 1.95Wrist/Colles’ fractures67 (2)50 (2)Spine fractures43 (1)22 (1)Hip fractures28 (1)26 (1)Cataracts182 (6)213 (7)0.850.69 to 1.04Vaginal Bleeding167 (5)317 (10)0.500.41 to 0.61Ischemic Cardiovascular Disease127 (4)104 (3)1.230.95 to 1.60Vaginal Discharge109 (4)408 (13)0.240.19 to 0.30Venous Thromboembolic events87 (3)140 (5)0.610.47 to 0.80Deep Venous Thromboembolic Events48 (2)74 (2)0.640.45 to 0.93Ischemic Cerebrovascular Event62 (2)88 (3)0.700.50 to 0.97Endometrial Cancer
- Percentages calculated based upon the numbers of patients with an intact uterus at baseline4 (0.2)13 (0.6)0.310.10 to 0.94Ischemic Cardiovascular EventsBetween treatment arms in the overall population of 6186 patients, there was no statistical difference in ischemic cardiovascular events (4% anastrozole vs. 3% tamoxifen). In the overall population, angina pectoris was reported in 71/3092 (2.3%) patients in the anastrozole arm and 51/3094 (1.6%) patients in the tamoxifen arm; myocardial infarction was reported in 37/3092 (1.2%) patients in the anastrozole arm and 34/3094 (1.1%) patients in the tamoxifen arm.In women with pre-existing ischemic heart disease 465/6186 (7.5%), the incidence of ischemic cardiovascular events was 17% in patients on anastrozole and 10% in patients on tamoxifen. In this patient population, angina pectoris was reported in 25/216 (11.6%) patients receiving anastrozole and 13/249 (5.2%) patients receiving tamoxifen; myocardial infarction was reported in 2/216 (0.9%) patients receiving anastrozole and 8/249 (3.2%) patients receiving tamoxifen.Bone Mineral Density FindingsResults from the ATAC trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline. Patients receiving tamoxifen had a mean increase in both lumbar spine and total hip BMD compared to baseline.Because anastrozole lowers circulating estrogen levels it may cause a reduction in bone mineral density. A post-marketing trial assessed the combined effects of anastrozole and the bisphosphonate risedronate on changes from baseline in BMD and markers of bone resorption and formation in postmenopausal women with hormone receptor-positive early breast cancer. All patients received calcium and vitamin D supplementation. At 12 months, small reductions in lumbar spine bone mineral density were noted in patients not receiving bisphosphonates. Bisphosphonate treatment preserved bone density in most patients at risk of fracture. Postmenopausal women with early breast cancer scheduled to be treated with anastrozole should have their bone status managed according to treatment guidelines already available for postmenopausal women at similar risk of fragility fracture.CholesterolDuring the ATAC trial, more patients receiving anastrozole were reported to have an elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively).A post-marketing trial also evaluated any potential effects of anastrozole on lipid profile. In the primary analysis population for lipids (anastrozole alone), there was no clinically significant change in LDL-C from baseline to 12 months and HDL-C from baseline to 12 months.In secondary population for lipids (anastrozole+risedronate), there also was no clinically significant change in LDL-C and HDL-C from baseline to 12 months. In both populations for lipids, there was no clinically significant difference in total cholesterol (TC) or serum triglycerides (TG) at 12 months compared with baseline. In this trial, treatment for 12 months with anastrozole alone had a neutral effect on lipid profile. Combination treatment with anastrozole and risedronate also had a neutral effect on lipid profile.The trial provides evidence that postmenopausal women with early breast cancer scheduled to be treated with anastrozole should be managed using the current National Cholesterol Education Program guidelines for cardiovascular risk-based management of individual patients with LDL elevations.Other Adverse ReactionsPatients receiving anastrozole had an increase in joint disorders (including arthritis, arthrosis and arthralgia) compared with patients receiving tamoxifen. Patients receiving anastrozole had an increase in the incidence of all fractures (specifically fractures of spine, hip and wrist) [315 (10%)] compared with patients receiving tamoxifen [209 (7%)]. Patients receiving anastrozole had a higher incidence of carpal tunnel syndrome [78 (2.5%)] compared with patients receiving tamoxifen [22 (0.7%)].Vaginal bleeding occurred more frequently in the tamoxifen-treated patients versus the anastrozole -treated patients 317 (10%) versus 167 (5%), respectively.Patients receiving anastrozole had a lower incidence of hot flashes, vaginal bleeding, vaginal discharge, endometrial cancer, venous thromboembolic events and ischemic cerebrovascular events compared with patients receiving tamoxifen.10-year median follow-up Safety Results from the ATAC TrialResults are consistent with the previous analyses.Serious adverse reactions were similar between anastrozole (50%) and tamoxifen (51%).Cardiovascular events were consistent with the known safety profiles of anastrozole and tamoxifen.The cumulative incidences of all first fractures (both serious and non-serious, occurring either during or after treatment) was higher in the anastrozole group (15%) compared to the tamoxifen group (11%). This increased first fracture rate during treatment did not continue in the post-treatment follow-up period.The cumulative incidence of new primary cancers was similar in the anastrozole group (13.7%) compared to the tamoxifen group (13.9%). Consistent with the previous analyses, endometrial cancer was higher in the tamoxifen group (0.8%) compared to the anastrozole group (0.2%).The overall number of deaths (during or off-trial treatment) was similar between the treatment groups. There were more deaths related to breast cancer in the tamoxifen than in the anastrozole treatment group.
Adverse reactions occurring with an incidence of at least 5% in either treatment group of trials 0030 and 0027 during or within 2 weeks of the end of treatment are shown in Table 3.Table 3 — Adverse Reactions Occurring with an Incidence of at Least 5% in Trials 0030 and 0027Body system Adverse Reaction
A patient may have had more than 1 adverse event.Number (%) of subjectsAnastrozole(N=506)Tamoxifen(N=511)Whole bodyAsthenia 83 (16)81 (16)Pain70 (14) 73 (14)Back pain60 (12)68 (13)Headache47 (9)40 (8)Abdominal pain40 (8)38 (7) Chest pain37 (7)37 (7)Flu syndrome35 (7)30 (6)Pelvic pain23 (5)30 (6)Cardiovascular Vasodilation128 (25)106 (21) Hypertension25 (5)36 (7)DigestiveNausea94 (19)106 (21)Constipation47 (9)66 (13)Diarrhea40 (8)33 (6)Vomiting38 (8)36 (7)Anorexia26 (5)46 (9)Metabolic and NutritionalPeripheral edema51 (10)41 (8)MusculoskeletalBone pain54 (11)52 (10)NervousDizziness30 (6)22 (4)Insomnia30 (6)38 (7)Depression23 (5)32 (6)Hypertonia16 (3)26 (5)RespiratoryCough increased55 (11)52 (10)Dyspnea51 (10)47 (9)Pharyngitis49 (10)68 (13)Skin and appendagesRash38 (8)34 (8)UrogenitalLeukorrhea9 (2) 31 (6)Less frequent adverse experiences reported in patients receiving anastrozole 1 mg in either Trial 0030 or Trial 0027 were similar to those reported for second-line therapy.Based on results from second-line therapy and the established safety profile of tamoxifen, the incidences of 9 pre-specified adverse event categories potentially causally related to one or both of the therapies because of their pharmacology were statistically analyzed. No significant differences were seen between treatment groups.Table 4 — Number of Patients with Pre-specified Adverse Reactions in Trials 0030 and 0027Number (n) and Percentage of PatientsAdverse Reaction
A patient may have had more than 1 adverse reaction.Anastrozole1 mg(N=506)n (%)NOLVADEX20 mg(N=511)n (%)Depression23 (5)32 (6)Tumor Flare15 (3)18 (4)Thromboembolic Disease
Includes pulmonary embolus, thrombophlebitis, retinal vein thrombosis.18 (4)33 (6) Venous
515 Coronary and Cerebral
Includes myocardial infarction, myocardial ischemia, angina pectoris, cerebrovascular accident, cerebral ischemia and cerebral infarct.1319Gastrointestinal Disturbance170 (34)196 (38)Hot Flushes134 (26)118 (23)Vaginal Dryness9 (2)3 (1)Lethargy6 (1)15 (3)Vaginal Bleeding5 (1)11 (2)Weight Gain11 (2)8 (2)
Anastrozole was tolerated in two controlled clinical trials (i.e., Trials 0004 and 0005), with less than 3.3% of the anastrozole-treated patients and 4.0% of the megestrol acetate-treated patients withdrawing due to an adverse reaction.The principal adverse reaction more common with anastrozole than megestrol acetate was diarrhea. Adverse reactions reported in greater than 5% of the patients in any of the treatment groups in these two controlled clinical trials, regardless of causality, are presented below:Table 5 — Number (N) and Percentage of Patients with Adverse Reactions in Trials 0004 and 0005
A patient may have had more than one adverse reactionAdverse ReactionAnastrozoleAnastrozoleMegesterol Acetate1 mg10 mg160 mg(N=262)(N=246)(N=253)n%n%n%Asthenia42(16)33(13)47(19)Nausea41(16)48(20)28(11)Headache34(13)44(18)24(9)Hot Flashes32(12)29(11)21(8)Pain28(11)38(15)29(11)Back Pain28(11)26(11)19(8)Dyspnea24(9)27(11)53(21)Vomiting24(9)26(11)16(6)Cough Increased22(8)18(7)19(8)Diarrhea22(8)18(7)7(3)Constipation18(7)18(7)21(8)Abdominal Pain18(7)14(6)18(7)Anorexia18(7)19(8)11(4)Bone Pain17(6)26(12)19(8)Pharyngitis16(6)23(9)15(6)Dizziness16(6)12(5)15(6)Rash15(6)15(6)19(8)Dry Mouth15(6)11(4)13(5)Peripheral Edema14(5)21(9)28(11)Pelvic Pain14(5)17(7)13(5)Depression14(5)6(2)5(2)Chest Pain13(5)18(7)13(5)Paresthesia12(5)15(6)9(4)Vaginal Hemorrhage6(2)4(2)13(5)Weight Gain4(2)9(4)30(12)Sweating4(2)3(1)16(6)Increased Appetite0(0)1(0)13(5)Other less frequent (2% to 5%) adverse reactions reported in patients receiving anastrozole 1 mg in either Trial 0004 or Trial 0005 are listed below. These adverse experiences are listed by body system and are in order of decreasing frequency within each body system regardless of assessed causality.Body as a Whole: Flu syndrome; fever; neck pain; malaise; accidental injury; infection
Cardiovascular: Hypertension; thrombophlebitis
Hepatic: Gamma GT increased; SGOT increased; SGPT increased
Hematologic: Anemia; leukopenia
Metabolic and Nutritional: Alkaline phosphatase increased; weight loss
Mean serum total cholesterol levels increased by 0.5 mmol/L among patients receiving anastrozole. Increases in LDL cholesterol have been shown to contribute to these changes.Musculoskeletal: Myalgia; arthralgia; pathological fracture
Nervous: Somnolence; confusion; insomnia; anxiety; nervousness
Respiratory: Sinusitis; bronchitis; rhinitis
Skin and Appendages: Hair thinning (alopecia); pruritus
Urogenital: Urinary tract infection; breast pain
The incidences of the following adverse reaction groups potentially causally related to one or both of the therapies because of their pharmacology, were statistically analyzed: weight gain, edema, thromboembolic disease, gastrointestinal disturbance, hot flushes, and vaginal dryness. These six groups, and the adverse reactions captured in the groups, were prospectively defined. The results are shown in the table below.Table 6 — Number (n) and Percentage of Patients with Pre-specified Adverse Reactions in Trials 0004 and 0005AnastrozoleAnastrozoleMegestrol Acetate1 mg10 mg160 mg(n=262)(n=246)(n=253)Adverse Reaction Groupn(%)n(%)n(%)Gastrointestinal Disturbance77(29)81(33)54(21)Hot Flushes33(13)29(12)35(14)Edema19(7)28(11)35(14)Thromboembolic Disease9(3)4(2)12(5)Vaginal Dryness5(2)3(1)2(1)Weight Gain4(2)10(4)30(12)
6.2 Post-Marketing Experience
These adverse reactions are reported voluntarily from a population of uncertain size. Therefore, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The following have been reported in post-approval use of anastrozole:Hepatobiliary events including increases in alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-GT, and bilirubin; hepatitis Rash including cases of mucocutaneous disorders such as erythema multiforme and Stevens-Johnson syndrome.Cases of allergic reactions including angioedema, urticaria and anaphylaxis.
[see Contraindications (
Myalgia, trigger finger and hypercalcemia (with or without an increase in parathyroid hormone)
Co-administration of anastrozole and tamoxifen in breast cancer patients reduced anastrozole plasma concentration by 27%. However, the co-administration of anastrozole and tamoxifen did not affect the pharmacokinetics of tamoxifen or N-desmethyltamoxifen. At a median follow-up of 33 months, the combination of anastrozole and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation. This treatment arm was discontinued from the trial.
[see Clinical Studies (
. Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole.
Estrogen-containing therapies should not be used with anastrozole as they may diminish its pharmacological action.
In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C
max and AUC), and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin.
7.4 Cytochrome P450
in vitro and
in vivo results, it is unlikely that co-administration of anastrozole 1 mg will affect other drugs as a result of inhibition of cytochrome P450
[see Clinical Pharmacology (
PREGNANCY CATEGORY X
[see Contraindications (
Anastrozole may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. Anastrozole is contraindicated in women who are or may become pregnant. In animal studies, anastrozole caused pregnancy failure, increased pregnancy loss, and signs of delayed fetal development. There are no studies of anastrozole use in pregnant women. If anastrozole is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus and potential risk for pregnancy loss.In animal reproduction studies, pregnant rats and rabbits received anastrozole during organogenesis at doses equal to or greater than 1 (rats) and 1/3 (rabbits) the recommended human dose on a mg/m
2 basis. In both species, anastrozole crossed the placenta, and there was increased pregnancy loss (increased pre- and/or post-implantation loss, increased resorption, and decreased numbers of live fetuses). In rats, these effects were dose related, and placental weights were significantly increased. Fetotoxicity, including delayed fetal development (i.e., incomplete ossification and depressed fetal body weights), occurred in rats at anastrozole doses that produced peak plasma levels 19 times higher than serum levels in humans at the therapeutic dose (AUC
0-24hr 9 times higher). In rabbits, anastrozole caused pregnancy failure at doses equal to or greater than 16 times the recommended human dose on a mg/m
[see Animal Toxicology and/or Pharmacology (
8.3 Nursing Mothers
It is not known if anastrozole is excreted in human milk. Because many drugs are excreted in human milk and because of the tumorigenicity shown for anastrozole in animal studies, or the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
8.4 Pediatric Use
Clinical studies in pediatric patients included a placebo-controlled trial in pubertal boys of adolescent age with gynecomastia and a single-arm trial in girls with McCune-Albright Syndrome and progressive precocious puberty. The efficacy of anastrozole in the treatment of pubertal gynecomastia in adolescent boys and in the treatment of precocious puberty in girls with McCune-Albright Syndrome has not been demonstrated.Gynecomastia StudyA randomized, double-blind, placebo-controlled, multi-center study enrolled 80 boys with pubertal gynecomastia aged 11 to 18 years. Patients were randomized to a daily regimen of either anastrozole 1 mg or placebo. After 6 months of treatment there was no statistically significant difference in the percentage of patients who experienced a ≥50% reduction in gynecomastia (primary efficacy analysis). Secondary efficacy analyses (absolute change in breast volume, the percentage of patients who had any reduction in the calculated volume of gynecomastia, breast pain resolution) were consistent with the primary efficacy analysis. Serum estradiol concentrations at Month 6 of treatment were reduced by 15.4% in the anastrozole group and 4.5% in the placebo group.Adverse reactions that were assessed as treatment-related by the investigators occurred in 16.3% of the anastrozole-treated patients and 8.1% of the placebo-treated patients with the most frequent being acne (7% anastrozole and 2.7% placebo) and headache (7% anastrozole and 0% placebo); all other adverse reactions showed small differences between treatment groups. One patient treated with anastrozole discontinued the trial because of testicular enlargement. The mean baseline-subtracted change in testicular volume after 6 months of treatment was + 6.6 ± 7.9 cm
3 in the anastrozole-treated patients and + 5.2 ± 8.0 cm
3 in the placebo group.
McCune-Albright Syndrome StudyA multi-center, single-arm, open-label study was conducted in 28 girls with McCune-Albright Syndrome and progressive precocious puberty aged 2 to <10 years. All patients received a 1 mg daily dose of anastrozole. The trial duration was 12 months. Patients were enrolled on the basis of a diagnosis of typical (27/28) or atypical (1/27) McCune-Albright Syndrome, precocious puberty, history of vaginal bleeding, and/or advanced bone age. Patients’ baseline characteristics included the following: a mean chronological age of 5.9 ± 2.0 years, a mean bone age of 8.6 ± 2.6 years, a mean growth rate of 7.9 ± 2.9 cm/year and a mean Tanner stage for breast of 2.7 ± 0.81. Compared to pre-treatment data there were no on-treatment statistically significant reductions in the frequency of vaginal bleeding days, or in the rate of increase of bone age (defined as a ratio between the change in bone age over the change of chronological age). There were no clinically significant changes in Tanner staging,mean ovarian volume, mean uterine volume and mean predicted adult height. A small but statistically significant reduction of growth rate from 7.9 ± 2.9 cm/year to 6.5 ± 2.8 cm/year was observed but the absence of a control group precludes attribution of this effect to treatment or to other confounding factors such as variations in endogenous estrogen levels commonly seen in McCune-Albright Syndrome patients.Five patients (18%) experienced adverse reactions that were considered possibly related to anastrozole. These were nausea, acne, pain in an extremity, increased alanine transaminase and aspartate transaminase, and allergic dermatitis.Pharmacokinetics in Pediatric PatientsFollowing 1 mg once daily multiple administration in pediatric patients, the mean time to reach the maximum anastrozole concentration was 1 hr. The mean (range) disposition parameters of anastrozole in pediatric patients were described by a CL/F of 1.54 L/h (0.77 to 4.53 L/h) and V/F of 98.4 L (50.7 to 330.0 L). The terminal elimination half-life was 46.8 h, which was similar to that observed in postmenopausal women treated with anastrozole for breast cancer. Based on a population pharmacokinetic analysis, the pharmacokinetics of anastrozole was similar in boys with pubertal gynecomastia and girls with McCune- Albright Syndrome.
8.5 Geriatric Use
In studies 0030 and 0027, about 50% of patients were 65 or older. Patients ≥ 65 years of age had moderately better tumor response and time to tumor progression than patients < 65 years of age regardless of randomized treatment. In studies 0004 and 0005, 50% of patients were 65 or older. Response rates and time to progression were similar for the over 65 and younger patients.In the ATAC study, 45% of patients were 65 years of age or older. The efficacy of anastrozole compared to tamoxifen in patients who were 65 years or older (N=1413 for anastrozole and N=1410 for tamoxifen, the hazard ratio for disease-free survival was 0.93 [95% CI: 0.80, 1.08]) was less than efficacy observed in patients who were less than 65 years of age (N=1712 for anastrozole and N=1706 for tamoxifen, the hazard ratio for disease-free survival was 0.79 [95% CI: 0.67, 0.94]). The pharmacokinetics of anastrozole is not affected by age.
8.6 Renal Impairment
Since only about 10% of anastrozole is excreted unchanged in the urine, the renal impairment does not influence the total body clearance. Dosage adjustment in patients with renal impairment is not necessary
[see Dosage and Administration (
2.1) and Clinical Pharmacology (
8.7 Hepatic Impairment
The plasma anastrozole concentrations in the subjects with hepatic cirrhosis were within the range of concentrations seen in normal subjects across all clinical trials. Therefore, dosage adjustment is also not necessary in patients with stable hepatic cirrhosis. Anastrozole has not been studied in patients with severe hepatic impairment
[see Dosage and Administration (
2.2) and Clinical Pharmacology (
Clinical trials have been conducted with anastrozole, up to 60 mg in a single dose given to healthy male volunteers and up to 10 mg daily given to postmenopausal women with advanced breast cancer; these dosages were tolerated. A single dose of anastrozole that results in life-threatening symptoms has not been established. There is no specific antidote to overdosage and treatment must be symptomatic. In the management of an overdose, consider that multiple agents may have been taken. Vomiting may be induced if the patient is alert. Dialysis may be helpful because anastrozole is not highly protein bound. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.
Anastrozole tablets, USP for oral administration contain 1 mg of anastrozole, a non-steroidal aromatase inhibitor. It is chemically described as 1,3-Benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl). Its molecular formula is C
5 and its structural formula is:
Anastrozole is an off-white powder with a molecular weight of 293.4. Anastrozole has moderate aqueous solubility (0.5 mg/mL at 25°C); solubility is independent of pH in the physiological range. Anastrozole is freely soluble in methanol, acetone, ethanol, and tetrahydrofuran, and very soluble in acetonitrile.Each tablet contains as inactive ingredients: lactose monohydrate, magnesium stearate, hypromellose, macrogol, povidone, sodium starch glycolate, and titanium dioxide.
12.1 Mechanism Of Action
The growth of many cancers of the breast is stimulated or maintained by estrogens.In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.
Effect On Estradiol
Mean serum concentrations of estradiol were evaluated in multiple daily dosing trials with 0.5, 1, 3, 5, and 10 mg of anastrozole in postmenopausal women with advanced breast cancer. Clinically significant suppression of serum estradiol was seen with all doses. Doses of 1 mg and higher resulted in suppression of mean serum concentrations of estradiol to the lower limit of detection (3.7 pmol/L). The recommended daily dose, anastrozole 1 mg, reduced estradiol by approximately 70% within 24 hours and by approximately 80% after 14 days of daily dosing. Suppression of serum estradiol was maintained for up to 6 days after cessation of daily dosing with anastrozole 1 mg.The effect of anastrozole in premenopausal women with early or advanced breast cancer has not been studied. Because aromatization of adrenal androgens is not a significant source of estradiol in premenopausal women, anastrozole would not be expected to lower estradiol levels in premenopausal women.
Effect On Corticosteroids
In multiple daily dosing trials with 3, 5, and 10 mg, the selectivity of anastrozole was assessed by examining effects on corticosteroid synthesis. For all doses, anastrozole did not affect cortisol or aldosterone secretion at baseline or in response to ACTH. No glucocorticoid or mineralocorticoid replacement therapy is necessary with anastrozole.
Other Endocrine Effects
In multiple daily dosing trials with 5 and 10 mg, thyroid stimulating hormone (TSH) was measured; there was no increase in TSH during the administration of anastrozole. Anastrozole does not possess direct progestogenic, androgenic, or estrogenic activity in animals, but does perturb the circulating levels of progesterone, androgens, and estrogens.
Inhibition of aromatase activity is primarily due to anastrozole, the parent drug. Absorption of anastrozole is rapid and maximum plasma concentrations typically occur within 2 hours of dosing under fasted conditions. Studies with radiolabeled drug have demonstrated that orally administered anastrozole is well absorbed into the systemic circulation. Food reduces the rate but not the overall extent of anastrozole absorption. The mean C
max of anastrozole decreased by 16% and the median T
max was delayed from 2 to 5 hours when anastrozole was administered 30 minutes after food. The pharmacokinetics of anastrozole are linear over the dose range of 1 to 20 mg, and do not change with repeated dosing. The pharmacokinetics of anastrozole were similar in patients and healthy volunteers.
Steady-state plasma levels are approximately 3- to 4-fold higher than levels observed after a single dose of anastrozole. Plasma concentrations approach steady-state levels at about 7 days of once daily dosing. Anastrozole is 40% bound to plasma proteins in the therapeutic range.
Metabolism of anastrozole occurs by N-dealkylation, hydroxylation and glucuronidation. Three metabolites of anastrozole (triazole, a glucuronide conjugate of hydroxy-anastrozole, and a glucuronide conjugate of anastrozole itself) have been identified in human plasma and urine. The major circulating metabolite of anastrozole, triazole, lacks pharmacologic activity.Anastrozole inhibited reactions catalyzed by cytochrome P450 1A2, 2C8/9, and 3A4 in vitro with Ki values which were approximately 30 times higher than the mean steady-state Cmax values observed following a 1 mg daily dose. Anastrozole had no inhibitory effect on reactions catalyzed by cytochrome P450 2A6 or 2D6 in vitro. Administration of a single 30 mg/kg or multiple 10 mg/kg doses of anastrozole to healthy subjects had no effect on the clearance of antipyrine or urinary recovery of antipyrine metabolites.
Eighty-five percent of radiolabeled anastrozole was recovered in feces and urine. Hepatic metabolism accounts for approximately 85% of anastrozole elimination. Renal elimination accounts for approximately 10% of total clearance. The mean elimination half-life of anastrozole is 50 hours.
Effect Of Gender And Age
Anastrozole pharmacokinetics have been investigated in postmenopausal female volunteers and patients with breast cancer. No age-related effects were seen over the range <50 to >80 years.
Effect Of Race
Estradiol and estrone sulfate serum levels were similar between Japanese and Caucasian postmenopausal women who received 1 mg of anastrozole daily for 16 days. Anastrozole mean steady-state minimum plasma concentrations in Caucasian and Japanese postmenopausal women were 25.7 and 30.4 ng/mL, respectively.
Effect Of Renal Impairment
Anastrozole pharmacokinetics have been investigated in subjects with renal impairment. Anastrozole renal clearance decreased proportionally with creatinine clearance and was approximately 50% lower in volunteers with severe renal impairment (creatinine clearance < 30 mL/min/1.73m2) compared to controls. Total clearance was only reduced 10%. No dosage adjustment is needed for renal impairment.
[see Dosage and Administration (
2.1) and Use in Specific Populations (
Effect Of Hepatic Impairment
Anastrozole pharmacokinetics have been investigated in subjects with hepatic cirrhosis related to alcohol abuse. The apparent oral clearance (CL/F) of anastrozole was approximately 30% lower in subjects with stable hepatic cirrhosis than in control subjects with normal liver function. However, these plasma concentrations were still with the range of values observed in normal subjects. The effect of severe hepatic impairment was not studied. No dose adjustment is necessary for stable hepatic cirrhosis.
[see Dosage and Administration (
2.2) and Use in Specific Populations (
13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility
A conventional carcinogenesis study in rats at doses of 1.0 to 25 mg/kg/day (about 10 to 243 times the daily maximum recommended human dose on a mg/m
2 basis) administered by oral gavage for up to 2 years revealed an increase in the incidence of hepatocellular adenoma and carcinoma and uterine stromal polyps in females and thyroid adenoma in males at the high dose. A dose-related increase was observed in the incidence of ovarian and uterine hyperplasia in females. At 25 mg/kg/day, plasma AUC
0-24 hr levels in rats were 110 to 125 times higher than the level exhibited in postmenopausal volunteers at the recommended dose. A separate carcinogenicity study in mice at oral doses of 5 to 50 mg/kg/day (about 24 to 243 times the daily maximum recommended human dose on a mg/m
2 basis) for up to 2 years produced an increase in the incidence of benign ovarian stromal, epithelial and granulosa cell tumors at all dose levels. A dose-related increase in the incidence of ovarian hyperplasia was also observed in female mice. These ovarian changes are considered to be rodent-specific effects of aromatase inhibition and are of questionable significance to humans. The incidence of lymphosarcoma was increased in males and females at the high dose. At 50 mg/kg/day, plasma AUC levels in mice were 35 to 40 times higher than the level exhibited in postmenopausal volunteers at the recommended dose.
Anastrozole has not been shown to be mutagenic in
in vitro tests (Ames and E. coli bacterial tests, CHO-K1 gene mutation assay) or clastogenic either
in vitro (chromosome aberrations in human lymphocytes) or
in vivo (micronucleus test in rats).
Oral administration of anastrozole to female rats (from 2 weeks before mating to pregnancy day 7) produced significant incidence of infertility and reduced numbers of viable pregnancies at 1 mg/kg/day (about 10 times the recommended human dose on a mg/m
2 basis and 9 times higher than the AUC
0-24 hr found in postmenopausal volunteers at the recommended dose). Pre-implantation loss of ova or fetus was increased at doses equal to or greater than 0.02 mg/kg/day (about one-fifth the recommended human dose on a mg/m
2 basis). Recovery of fertility was observed following a 5-week non-dosing period which followed 3 weeks of dosing. It is not known whether these effects observed in female rats are indicative of impaired fertility in humans.
Multiple-dose studies in rats administered anastrozole for 6 months at doses equal to or greater than 1 mg/kg/day (which produced plasma anastrozole C
ssmax and AUC
0-24 hr that were 19 and 9 times higher than the respective values found in postmenopausal volunteers at the recommended dose) resulted in hypertrophy of the ovaries and the presence of follicular cysts. In addition, hyperplastic uteri were observed in 6-month studies in female dogs administered doses equal to or greater than 1 mg/kg/day (which produced plasma anastrozole C
ssmax and AUC
0-24 hr that were 22 times and 16 times higher than the respective values found in postmenopausal women at the recommended dose). It is not known whether these effects on the reproductive organs of animals are associated with impaired fertility in premenopausal women.
13.2 Animal Toxicology And/Or Pharmacology
Reproductive ToxicologyAnastrozole has been found to cross the placenta following oral administration of 0.1 mg/kg in rats and rabbits (about 1 and 1.9 times the recommended human dose, respectively, on a mg/m
2 basis). Studies in both rats and rabbits at doses equal to or greater than 0.1 and 0.02 mg/kg/day, respectively (about 1 and 1/3, respectively, the recommended human dose on a mg/m
2 basis), administered during the period of organogenesis showed that anastrozole increased pregnancy loss (increased pre- and/or post-implantation loss, increased resorption, and decreased numbers of live fetuses); effects were dose related in rats. Placental weights were significantly increased in rats at doses of 0.1 mg/kg/day or more.
Evidence of fetotoxicity, including delayed fetal development (i.e., incomplete ossification and depressed fetal body weights), was observed in rats administered doses of 1 mg/kg/day (which produced plasma anastrozole C
ssmax and AUC
0-24 hr that were 19 times and 9 times higher than the respective values found in postmenopausal volunteers at the recommended dose). There was no evidence of teratogenicity in rats administered doses up to 1.0 mg/kg/day. In rabbits, anastrozole caused pregnancy failure at doses equal to or greater than 1.0 mg/kg/day (about 16 times the recommended human dose on a mg/m
2 basis); there was no evidence of teratogenicity in rabbits administered 0.2 mg/kg/day (about 3 times the recommended human dose on a mg/m
14.1 Adjuvant Treatment Of Breast Cancer In Postmenopausal Women
A multicenter, double-blind trial (ATAC) randomized 9,366 postmenopausal women with operable breast cancer to adjuvant treatment with anastrozole 1 mg daily, tamoxifen 20 mg daily, or a combination of the two treatments for five years or until recurrence of the disease. The primary endpoint of the trial was disease-free survival (ie, time to occurrence of a distant or local recurrence, or contralateral breast cancer or death from any cause). Secondary endpoints of the trial included distant disease-free survival, the incidence of contralateral breast cancer and overall survival. At a median follow-up of 33 months, the combination of anastrozole and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor positive subpopulation. This treatment arm was discontinued from the trial. Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole
[see Drug Interactions (
Demographic and other baseline characteristics were similar among the three treatment groups (see Table
Table 7 - Demographic and Baseline Characteristics for ATAC TrialDemographic CharacteristicAnastrozole1 mg(N
N=Number of patients randomized to the treatment=3125)
Anastrozole 1 mgplus Tamoxifen20 mg
The combination arm was discontinued due to lack of efficacy benefit at 33 months of follow-up(N
Mean age (yrs.)22.214.171.124Age Range (yrs.)38.1 to 92.832.8 to 94.937 to 92.2Age Distribution (%) <45 yrs.0.70.40.5 45 to 60 yrs.34.635.034.5 >60 <70 yrs.38.037.137.7 >70 yrs.26.727.427.3Mean Weight (kg)70.871.171.3Receptor Status (%) Positive
Includes patients who were estrogen receptor (ER) positive or progesterone receptor (PgR) positive, or both positive83.583.184.0 Negative
Includes patients with both ER negative and PgR negative receptor status 7.48.07.0 Other
Includes all other combinations of ER and PgR receptor status unknown8.88.6 9.0Other Treatment (%) prior to Randomization Mastectomy47.847.348.1 Breast conservation
Among the patients who had breast conservation, radiotherapy was administered to 95.0% of patients in the anastrozole arm, 94.1% in the tamoxifen arm and 94.5% in the anastrozole plus tamoxifen arm.52.352.851.9 Axillary surgery95.595.795.2 Radiotherapy63.362.561.9 Chemotherapy22.320.820.8 Neoadjuvant Tamoxifen126.96.36.199Primary Tumor Size (%) T1 (≤2 cm)63.962.964.1 T2 (>2 cm and ≤5 cm)32.634.232.9 T3 (>5 cm)188.8.131.52Nodal Status (%) Node positive34.933.633.5 1 to 3 (# of nodes)24.424.424.34 to 184.108.40.206 >220.127.116.11Tumor Grade (%) Well-differentiated20.820.521.2 Moderately differentiated46.847.8 46.5 Poorly/undifferentiated23.723.323.7Not assessed/recorded18.104.22.168Patients in the two monotherapy arms of the ATAC trial were treated for a median of 60 months (5 years) and followed for a median of 68 months. Disease-free survival in the intent- to-treat population was statistically significantly improved [Hazard Ratio (HR) = 0.87, 95% CI: 0.78, 0.97, p=0.0127] in the anastrozole arm compared to the tamoxifen arm. In the hormone receptor-positive subpopulation representing about 84% of the trial patients, disease-free survival was also statistically significantly improved (HR =0.83, 95% CI: 0.73, 0.94, p=0.0049) in the anastrozole arm compared to the tamoxifen arm.Figure 1- Disease-Free Survival Kaplan Meier Survival Curve for all Patients Randomized to Anastrozole or Tamoxifen Monotherapy in the ATAC trial (Intent-to-Treat)Figure 2- Disease-free Survival for Hormone Receptor-Positive Subpopulation of Patients Randomized to Anastrozole or Tamoxifen Monotherapy in the ATAC TrialThe survival data with 68 months follow-up is presented in Table 9.In the group of patients who had previous adjuvant chemotherapy (N=698 for anastrozole and N=647 for tamoxifen), the hazard ratio for disease-free survival was 0.91 (95% CI: 0.73 to 1.13) in the anastrozole arm compared to the tamoxifen arm. The frequency of individual events in the intent-to-treat population and the hormone receptor-positive subpopulation are described in Table 8. Table 8 - All Recurrence and Death Events
The combination arm was discontinued due to lack of efficacy benefit at 33 months of follow-up.Intent-To-Treat Population
Patients may fall into more than one category.Hormone Receptor-Positive Subpopulation
N=Number of patients randomized=3125)
Tamoxifen 20 mg(N
Number (%) of PatientsNumber (%) of PatientsMedian Duration of Therapy (mo)60606060Median EfficacyFollow-up (mo)68686868Loco-regional recurrence119 (3.8)149 (4.8)76 (2.9)101 (3.9)Contralateral breast cancer35 (1.1)59 (1.9)26 (1.0)54 (2.1) Invasive27 (0.9)52 (1.7)21 (0.8)48 (1.8) Ductal carcinoma in situ8 (0.3)6 (0.2)5 (0.2)5 (0.2) Unknown01 (<0.1)01 (<0.1)Distant recurrence324 (10.4)375 (12.0)226 (8.6)265 (10.2)Death from Any Cause411 (13.2)420 (13.5)296 (11.3)301 (11.6) Death breast cancer218 (7.0)248 (8.0)138 (5.3)160 (6.2) Death other reason (including unknown)193 (6.2)172 (5.5)158 (6.0)141 (5.4)A summary of the study efficacy results is provided in Table 9.Table 9 - ATAC Efficacy Summary
The combination arm was discontinued due to lack of efficacy benefit at 33 months of follow-up.Intent-To-Treat PopulationHormone Receptor-Positive SubpopulationAnastrozole 1 mg(N=3125)Tamoxifen20 mg(N=3116)Anastrozole1 mg(N=2618)Tamoxifen20 mg(N=2598)Number of EventsNumber of EventsDisease-free Survival575 651 424 497 Hazard ratio0.870.78 to 0.970.01270.830.73 to 0.940.0049 2-sided 95% CI p-valueDistant Disease-free Survival500 530370394Hazard ratio0.940.83 to 1.060.930.80 to 1.072-sided 95% CIOverall Survival411420296301 Hazard ratio 0.970.85 to 1.120.970.83 to 1.14 2-sided 95% CI10-year median follow-up Efficacy Results from the ATAC Trial In a subsequent analysis of the ATAC trial, patients in the two monotherapy arms were followed for a median of 120 months (10 years). Patients received study treatment for a median of 60 months (5 years) (see Table 10).Table 10 - Efficacy SummaryIntent-To-Treat PopulationHormone Receptor-Positive SubpopulationAnastrozole1 mg(N=3125)Tamoxifen20 mg(N=3116) Anastrozole 1 mg(N=2618)Tamoxifen20 mg(N=2598)Number of EventsNumber of EventsDisease-free Survival953 1022 735924 Hazard ratio0.910.86 2-sided 95% CI0.83 to 0.990.78 to 0.95 p-value0.03650.0027Overall Survival734 747563586 Hazard ratio 0.970.88 to 1.080.950.84 to 1.06 2-sided 95% CIFigure 3 - Disease-Free Survival Kaplan Meier Survival Curve for all Patients Randomized to Anastrozole or Tamoxifen Monotherapy in the ATAC Trial (Intent-to-Treat)
(a)a The proportion of patients with 120 months’ follow-up was 29.4%.
Figure 4 - Disease-Free Survival for Hormone Receptor-Positive Subpopulation of Patients Randomized to Anastrozole or Tamoxifen Monotherapy in the ATAC Trial
(b)bThe proportion of patients with 120 months’ follow-up was 29.8%.
14.2 First Line Therapy In Postmenopausal Women With Advanced Breast Cancer
Two double-blind, controlled clinical studies of similar design (0030, a North American study and 0027, a predominately European study) were conducted to assess the efficacy of anastrozole compared with tamoxifen as first-line therapy for hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer in postmenopausal women. A total of 1021 patients between the ages of 30 and 92 years old were randomized to receive trial treatment. Patients were randomized to receive 1 mg of anastrozole once daily or 20 mg of tamoxifen once daily. The primary endpoints for both trials were time to tumor progression, objective tumor response rate, and safety.Demographics and other baseline characteristics, including patients who had measurable and no measurable disease, patients who were given previous adjuvant therapy, the site of metastatic disease and ethnic origin were similar for the two treatment groups for both trials. The following table summarizes the hormone receptor status at entry for all randomized patients in trials 0030 and 0027.Table 11 – Demographic and Other Baseline CharacteristicsNumber (%) of subjectsTrial 0030Trial 0027Receptor statusAnastrozole1 mg(n=171)Tamoxifen20 mg(n=182)Anastrozole1 mg(n=340)Tamoxifen20 mg(n=328)ER
ER=Estrogen receptor and/or PgR
PgR=Progesterone receptor151 (88.3)162 (89.0)154 (45.3)144 (43.9)ER
unknown19 (11.1)20 (11.0)185 (54.4)183 (55.8)For the primary endpoints, trial 0030 showed that anastrozole had a statistically significant advantage over tamoxifen (p=0.006) for time to tumor progression; objective tumor response rates were similar for anastrozole and tamoxifen. Trial 0027 showed that anastrozole and tamoxifen had similar objective tumor response rates and time to tumor progression (see
Table 12 and Figures
Table 12 below summarizes the results of trial 0030 and trial 0027 for the primary efficacy endpoints.Table 12– Efficacy Results of First-line TreatmentEnd pointTrial 0030Trial 0027Anastrozole1 mg(n=171)Tamoxifen20 mg(n=182)Anastrozole1 mg(n=340)Tamoxifen20 mg(n=328)Time to progression (TTP) Median TTP (months)22.214.171.124.3Number (%) of subjectswho progressed114 (67%)138 (76%)249 (73%)247 (75%)Hazard ratio (LCL
LCL=Lower Confidence Limit )
Tamoxifen:Anastrozole1.42 (1.15)1.01 (0.87)2-sided 95% CI
CI=Confidence Interval(1.11, 1.82)(0.85, 1.20)p-value
Two-sided Log Rank0.0060.920Best objective response rateNumber (%) of subjects With CR
CR=Complete Response + PR
PR=Partial Response36 (21.1%)31 (17.0%)112 (32.9%)107 (32.6%)Odds Ratio (LCL
Anastrozole:Tamoxifen1.30 (0.83)1.01 (0.77)Figure 5 — Kaplan-Meier probability of time to disease progression for all randomized patients (intent to- treat) in Trial 0030Figure 6 — Kaplan-Meier probability of time to progression for all randomized patients (intent-to-treat) in Trial 0027Results from the secondary endpoints were supportive of the results of the primary efficacy endpoints. There were too few deaths occurring across treatment groups of both trials to draw conclusions on overall survival differences.
14.3 Second Line Therapy In Postmenopausal Women With Advanced Breast Cancer Who Had Disease Progression Following Tamoxifen Therapy
Anastrozole was studied in two controlled clinical trials (0004, a North American study; 0005, a predominately European study) in postmenopausal women with advanced breast cancer who had disease progression following tamoxifen therapy for either advanced or early breast cancer. Some of the patients had also received previous cytotoxic treatment. Most patients were ER-positive; a smaller fraction were ER-unknown or ER-negative; the ER-negative patients were eligible only if they had a positive response to tamoxifen. Eligible patients with measurable and non-measurable disease were randomized to receive either a single daily dose of 1 mg or 10 mg of anastrozole. or megestrol acetate 40 mg four times a day. The studies were double-blinded with respect to anastrozole. Time to progression and objective response (only patients with measurable disease could be considered partial responders) rates were the primary efficacy variables. Objective response rates were cal
culated based on the Union Internationale Contre le Cancer (UICC) criteria. The rate of prolonged (more than 24 weeks) stable disease, the rate of progression, and survival were also calculated.Both trials included over 375 patients; demographics and other baseline characteristics were similar for the three treatment groups in each trial. Patients in the 0005 trial had responded better to prior tamoxifen treatment. Of the patients entered who had prior tamoxifen therapy for advanced disease (58% in Trial 0004; 57% in Trial 0005), 18% of these patients in Trial 0004 and 42% in Trial 0005 were reported by the primary investigator to have responded. In Trial 0004, 81% of patients were ER-positive, 13% were ER-unknown, and 6% were ER-negative. In Trial 0005, 58% of patients were ER-positive, 37% were ER-unknown, and 5% were ER-negative. In Trial 0004, 62% of patients had measurable disease compared to 79% in Trial 0005. The sites of metastatic disease were similar among treatment groups for each trial. On average, 40% of the patients had soft tissue metastases; 60% had bone metastases; and 40% had visceral (15% liver) metastases.Efficacy results from the two studies were similar as presented in
Table 13. In both studies there were no significant differences between treatment arms with respect to any of the efficacy parameters listed in the table below.
Table 13– Efficacy Results of Second-line TreatmentAnastrozole1 mgAnastrozole10 mgMegestrolAcetate160 mgTrial 0004(
(N=128)(N=130)(N=128)Median Follow-up (months)
Surviving Patients31.330.932.9Median Time to Death (months)29.625.726.72 Year Survival Probability (%)62.058.053.1Median Time to Progression (months)126.96.36.199Objective Response (all patients ) (%)12.510.010.2Stable Disease for >24 weeks (%)188.8.131.52Progression (%)86.785.490.6Trial 0005(
Europe, Australia, S. Africa)
(N=135)(N=118)(N=125)Median Follow-up (months)
31.030.931.5Median Time to Death (months)24.324.819.82 Year Survival Probability (%)50.550.939.1Median Time to Progression (months)184.108.40.206Objective Response (all patients) (%)12.615.314.4Stable Disease for >24 weeks (%)24.425.423.2Progression (%)91.989.892.0When data from the two controlled trials are pooled, the objective response rates and median times to progression and death were similar for patients randomized to anastrozole 1 mg and megestrol acetate. There is, in this data, no indication that anastrozole 10 mg is superior to anastrozole 1 mg.Table 14 – Pooled Efficacy Results of Second-line TreatmentTrials 0004 & 0005(Pooled Data)Anastrozole 1 mgN=263Anastrozole 10 mgN=248Megestrol Acetate160 mgN=253Median Time toDeath (months)26.725.522.52 Year SurvivalProbability (%)56.154.646.3Median Time toProgression220.127.116.11Objective Response(all patients) (%)12.512.512.3
16 How Supplied/Storage And Handling
Product: 50090-2453NDC: 50090-2453-0 30 TABLET in a BOTTLE, PLASTIC NDC: 50090-2453-1 90 TABLET in a BOTTLE, PLASTIC
17 Patient Counseling Information
“See FDA approved patient labeling (Patient Information).”
Patients should be advised that anastrozole may cause fetal harm. They should also be advised that anastrozole is not for use in premenopausal women; therefore, if they become pregnant, they should stop taking anastrozole tablets and immediately contact their doctor.
17.2 Allergic (Hypersensitivity) Reactions
Patients should be informed of the possibility of serious allergic reactions with swelling of the face, lips, tongue and/or throat (angioedema) which may cause difficulty in swallowing and/or breathing and to seek medical attention immediately.
17.3 Ischemic Cardiovascular Events
Patients with pre-existing ischemic heart disease should be informed that an increased incidence of cardiovascular events has been observed with anastrozole use compared to tamoxifen use. If patients have new or worsening chest pain or shortness of breath they should seek medical attention immediately.
17.4 Bone Effects
Patients should be informed that anastrozole lowers the level of estrogen. This may lead to a loss of the mineral content of bones, which might decrease bone strength. A possible consequence of decreased mineral content of bones is an increase in the risk of fractures.
Patients should be informed that an increased level of cholesterol might be seen while receiving anastrozole.
17.6 Tickling, Tingling Or Numbness
Patients should be informed that if they experience tickling, tingling, or numbness they should notify their health care provider.
Patients should be advised not to take anastrozole with tamoxifen.
17.8 Missed Doses
Inform patients that if they miss a dose, take it as soon as they remember. If it is almost time for their next dose, skip the missed dose and take the next regularly scheduled dose. Patients should not take two doses at the same time.
* Please review the disclaimer below.